Trials / Completed
CompletedNCT00104091
Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors
A Multicenter Phase II Study of TP-38 in Those Patients With Glioblastoma Multiforme Who Have Recurred or Progressed After Previous Resection and Radiation Therapy and Are Scheduled for Gross Total Resection
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 56 (estimated)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Immunotoxin therapy may be effective in treating malignant glioma. Immunotoxins can locate tumor cells and kill them without harming normal cells.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TP-38 | TP-38 is a recombinant chimeric protein composed of the epidermal growth factor (EGFR) binding ligand (TGF-α)and a genetically engineered form of the Pseudomonas exotoxin, PE-38. |
Timeline
- Start date
- 2004-12-01
- Primary completion
- 2007-04-01
- Completion
- 2007-06-01
- First posted
- 2005-02-23
- Last updated
- 2011-05-23
Source: ClinicalTrials.gov record NCT00104091. Inclusion in this directory is not an endorsement.